Skip to content
drillr.ai
Sign up

02616.HK

CStone Pharmaceuticals

HKSE · Healthcare · Biotechnology · CN

HKD 6.19
+0.16%
Ask drillr

  • Aug 27, 2026, 11:39 UTC

    CStone Pharmaceuticals reported interim results for the six months ended June 2026, with revenue of RMB 205 million, up 315% year-on-year, and a narrowed net loss of RMB 252 million.

    Source:

  • Jul 22, 2026, 23:39 UTC

    CStone Pharmaceuticals repurchased 4.597 million shares in the open market last month, all intended for cancellation.

    Source: